More importantly, our study provides a theoretical basis for MRE11:p.K464R mutation as a specific indicator for resistance monitoring of Olaparib, which is expected to optimize the application performance of PARP inhibitors and achieve more accurate treatment and prognosis for ovarian cancer. Here, PARP1 is linked to ovarian cancer.